Latest news with #Lakshminarayan
Time of India
21-05-2025
- Politics
- Time of India
Aaditya criticises BMC over temple demolition notice
Mumbai: Worli MLA Aaditya Thackeray on Wednesday alleged that despite there being enough space for redevelopment of a building, the BMC has threatened the 100-year-old Lakshminarayan temple in the area with a demolition notice. "I visited the temple today and interacted with the locals. We will ensure that the sale component work will not happen for the builder if the temple is touched. The larger question for all to think about is how, under the BJP's electoral Hindutva, temples in Maharashtra are under threat!" he said. According to BMC officials, the temple is being relocated as part of the larger redevelopment plan, in accordance with the admissible area. "This matter also reached the city civil court, but temple authorities withdrew their petition. The developer gave a written assurance that the temple will be relocated within the designated area," said a civic Mumbai: Worli MLA Aaditya Thackeray on Wednesday alleged that despite there being enough space for redevelopment of a building, the BMC has threatened the 100-year-old Lakshminarayan temple in the area with a demolition notice. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ative sua licença do antivírus agora Clique aqui Undo "I visited the temple today and interacted with the locals. We will ensure that the sale component work will not happen for the builder if the temple is touched. The larger question for all to think about is how, under the BJP's electoral Hindutva, temples in Maharashtra are under threat!" he said. According to BMC officials, the temple is being relocated as part of the larger redevelopment plan, in accordance with the admissible area. "This matter also reached the city civil court, but temple authorities withdrew their petition. The developer gave a written assurance that the temple will be relocated within the designated area," said a civic
Time of India
25-04-2025
- Business
- Time of India
India launches biodegradable tax stamp to reduce plastic use in liquor labeling
India has developed a new biodegradable tax stamp to replace plastic-based security labels widely used in the country's liquor industry. The move, led by a government agency, aims to reduce plastic use and support India's sustainability goals. With over 30 billion tax stamps used each year—mostly made from polyester—this shift could significantly cut plastic waste while strengthening security in excise labeling . #Pahalgam Terrorist Attack India pulled the plug on IWT when Pakistanis are fighting over water What makes this India-Pakistan standoff more dangerous than past ones The problem of Pakistan couldn't have come at a worse time for D-St Government-backed material replaces plastic tax stamps A new tax stamp made from biodegradable engineered paper has been introduced by the National Research Development Corporation (NRDC), which works under the Ministry of Science and Technology. The stamp is plastic-free and includes tamper-evident layers, QR codes, high-security inks, and holographic features. It is already being used in Ladakh and is expected to be adopted more widely in India. 'We have already supplied over 1 crore 'green' labels (tax stamps) to Ladakh and are currently supplying more than 4 crore such labels each quarter to the Uttarakhand government. NRDC is also the nodal partner of (World Intellectual Property Organisation) WIPO Green. Here we identify the green technologies all over the world and put them in the WIPO database,' said Lakshminarayan, Business Development head of NRDC. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Part of India's larger green strategy India's liquor labeling system has long relied on plastic-based stamps, even as the country banned many single-use plastics. This innovation offers a domestic alternative that matches global environmental standards and supports India's goal of reducing its plastic footprint. The biodegradable stamp is part of a broader national policy shift. Under Prime Minister Narendra Modi, India has increased efforts to integrate green technologies across sectors. Programmes such as Make in India and Atmanirbhar Bharat are now being aligned with eco-friendly product development. Live Events 'Biodegradable tax stamp developed by NRDC is a part of India's initiation into regenerative economy which is going to be an essential component of the next industrial revolution,' said Union Minister of State for Science and Technology Dr. Jitendra Singh. NRDC, working since 1953 on research for industrial use products, is also exploring the use of biodegradable stamp technology beyond liquor excise labeling. Future uses may include pharmaceutical packaging, agrochemical labeling, and food-grade applications. The agency is also planning to secure international intellectual property rights and explore export licensing, especially in countries involved in the UNEP's plastic treaty or the EU's circular economy plans. Large-scale use and export potential India currently uses the highest number of liquor tax stamps globally. About 60% are plastic-based, while 40% are paper-based. The new biodegradable stamp, known as BioSHEAL , is now in the commercial pilot stage. It includes dual QR codes and anti-counterfeiting features that support both physical and digital tracking—what the industry refers to as 'phygital' labeling. Phygital labels are gaining traction States like Kerala are working on hybrid security labels. The Centre for Development of Imaging Technology (C-DIT) has created the THTT (Taggant, Hologram, Track and Trace) stamp. Meanwhile, Delhi and Uttar Pradesh had adopted thermal transfer labels but later revised their strategies due to counterfeiting issues. The NRDC is working with excise departments, exporters, and industry partners to expand the use of the new stamp. It is also developing other green intellectual property for sectors such as agriculture and healthcare.
Irish Daily Mirror
25-04-2025
- Health
- Irish Daily Mirror
Irish people warned common drug increases dementia risk by a third
A new study suggests that prolonged use of a common acid reflux drug could heighten the risk of dementia by a third. Researchers discovered that individuals taking proton pump inhibitors (PPIs) for over 4.4 years had a 33% increased chance of being diagnosed with dementia. PPIs are frequently prescribed to treat acid reflux, which occurs when stomach acid backs up into the oesophagus, often leading to heartburn or ulcers. Persistent acid reflux can evolve into gastroesophageal reflux disease (GORD), affecting up to 20% of people in Ireland and potentially raising the risk of oesophageal cancer. These drugs aim to suppress acid production by acting on stomach lining enzymes. Despite their effectiveness, PPIs have been previously associated with various health issues, including strokes, bone fractures, and kidney disease. Published in the journal Neurology, the study does not establish a direct causal link but points out a strong correlation, as reported by SurreyLive, reports the Mirror. The study's lead author, Professor Kamakshi Lakshminarayan from the University of Minnesota, stated: "Proton pump inhibitors are useful for managing acid reflux, but long-term use has been tied to several health concerns. In this study, we wanted to explore whether they could also be linked to dementia." The study spanned over 5,700 participants aged 45 and above, all dementia-free at inception. With a mean age of 75, the usage of Proton Pump Inhibitors (PPIs) by these individuals was tracked through both in-person sessions and yearly telephonic updates. Out of the cohort, 1,490 participants (26%) were PPI users, grouped by usage duration: up to 2.8 years, between 2.8 and 4.4 years, and beyond 4.4 years. Throughout the 5.5-year average tracking period, dementia developed in 585 of the participants (10%). For those on PPIs past the 4.4-year mark, dementia appeared in 24 out of every 1,000 person-years, versus 19 per 1,000 for non-users. Even when accounting for variables such as age, gender, ethnicity, and underlying conditions like hypertension and diabetes, researchers found a 33% uptick in dementia risk among long-term PPI consumers. However, this heightened risk did not present for shorter-term users under the 4.4-year threshold. Professor Lakshminarayan stressed the necessity of professional medical advice before altering any treatment regimen. "There are alternative ways to manage acid reflux, including antacids, diet changes, and maintaining a healthy weight," she outlined. "But not all approaches work for everyone. Anyone taking these medications should speak with their doctor first, as stopping PPIs suddenly can worsen symptoms." She further noted the need for additional studies to elucidate the connection and its underlying mechanisms. Subscribe to our newsletter for the latest news from the Irish Mirror direct to your inbox: Sign up here.
Daily Record
25-04-2025
- Health
- Daily Record
The common medication scientists warn could be increasing your risk of dementia
A worrying study has found that a common medication could put people at higher risk of developing dementia . Long-term use of a standard acid reflux table may increase the risk of the degenerative disease by as much as a third, according to the new research. The study, which was published in the Neurology journal, found that those using proton pump inhibitors (PPIs) for a period of more than 4.4 years were 33 per cent more likely to be diagnosed with the incurable condition. PPIs are a widely-used medication in the treatment of acid reflux, where stomach acid flows up into the oesophagus and often causes heartburn or painful ulcers. Regular reflux can lead to gastroesophageal reflux disease, a condition which can lead to oesophageal cancer, Surrey Live reports. The medication targets enzymes in the stomach lining to reduce acid production and decrease the risk of reflux. Although they are an effective treatment, PPIs have previously been linked to health risks including stroke, bone fractures, and kidney disease. The new research, led by a team from the University of Minnesota, didn't prove a direct cause-and-effect relationship between PPIs and dementia, but did highlight a link between the two. Professor Kamakshi Lakshminarayan, a vascular neurologist from the American university and lead author of the study, revealed that the team wanted to analyse any potential link due to the other health concerns previously associated with the medication. She said: "Proton pump inhibitors are useful for managing acid reflux, but long-term use has been tied to several health concerns. In this study, we wanted to explore whether they could also be linked to dementia.' More than 5,700 participants aged 45 and older were involved in the large-scale study. When the research began, none of them had been diagnosed with dementia. The team used in-person study visits and annual phone check-ins to monitor the use of PPIs in the participants, who had an average age of 75. Of the group, 1,490 (26%) had taken PPIs and were categorised by duration of use: up to 2.8 years, between 2.8 and 4.4 years, and more than 4.4 years. Over an average follow-up of 5.5 years, 585 participants (10%) developed dementia. Among those who used PPIs for more than 4.4 years, 24 out of every 1,000 person-years developed dementia, compared to 19 per 1,000 person-years in those who didn't take the medication. The research team adjusted for a variety of factors, including age, gender, race, and conditions like high blood pressure and diabetes, and were able to conclude that there was a 33 per cent higher risk of dementia in the long-term PPI users. No increased risk was found for those who took the drugs for less than 4.4 years. But despite the results, Professor Lakshminarayan highlighted the importance of consulting a doctor before making any changes to treatment. She said: 'There are alternative ways to manage acid reflux, including antacids, diet changes, and maintaining a healthy weight. But not all approaches work for everyone. "Anyone taking these medications should speak with their doctor first, as stopping PPIs suddenly can worsen symptoms.' She also added that more research is required to better understand the link between the medication and dementia, as well as the mechanisms behind it.
Daily Mirror
25-04-2025
- Health
- Daily Mirror
Neurologist's stark warning over drug millions take increasing dementia risk
Neurologists have discovered that a common household drug, which has been previously linked to higher risk of stroke, broken bones and kidney disease, could increase dementia risk Long-term use of a common acid reflux medication may increase the risk of developing dementia by one-third, according to new research. The study found that people who used proton pump inhibitors (PPIs) for more than 4.4 years were 33% more likely to be diagnosed with the condition. PPIs are widely used to treat acid reflux - a condition where stomach acid flows into the oesophagus, often causing heartburn or ulcers. Frequent acid reflux can lead to gastroesophageal reflux disease (GORD), a condition that affects up to 40% of the UK population and may increase the risk of oesophageal cancer. These medications work by targeting enzymes in the stomach lining to reduce acid production. While effective, PPIs have previously been linked to health risks including stroke, bone fractures, and kidney disease. The new study, published in the journal Neurology , doesn't confirm a direct cause-and-effect relationship but does highlight a significant association, reports SurreyLive. Lead author Professor Kamakshi Lakshminarayan, a vascular neurologist from the University of Minnesota, explained: 'Proton pump inhibitors are useful for managing acid reflux, but long-term use has been tied to several health concerns. In this study, we wanted to explore whether they could also be linked to dementia.' The research involved over 5,700 participants aged 45 and older who were dementia-free at the start of the study. With an average age of 75, participants' use of PPIs was monitored through in-person study visits and annual phone check-ins. Of the group, 1,490 (26%) had taken PPIs and were categorised by duration of use: up to 2.8 years, between 2.8 and 4.4 years, and more than 4.4 years. Over an average follow-up of 5.5 years, 585 participants (10%) developed dementia. Among those who used PPIs for more than 4.4 years, 24 out of every 1,000 person-years developed dementia, compared to 19 per 1,000 person-years in those who never took the drugs. After adjusting for factors like age, sex, race, and health conditions such as high blood pressure and diabetes, the researchers concluded there was a 33% higher risk of dementia in the long-term PPI users. No increased risk was found for those who took the drugs for less than 4.4 years. Professor Lakshminarayan emphasised the importance of consulting a doctor before making any changes to treatment. 'There are alternative ways to manage acid reflux, including antacids, diet changes, and maintaining a healthy weight,' she said. 'But not all approaches work for everyone. Anyone taking these medications should speak with their doctor first, as stopping PPIs suddenly can worsen symptoms.' More research is needed to better understand the link and the mechanisms behind it, she added.
